Navigation Links
Iron-regulating protein is strong predictor of breast cancer prognosis, study shows

WINSTON-SALEM, N.C. Wednesday, Aug. 4, 2010 A new study by researchers at Wake Forest University Baptist Medical Center (WFUBMC) may soon help to spare some women with breast cancer from having to undergo invasive and toxic treatments for their disease.

Investigators found that low levels of ferroportin, the only known protein to eliminate iron from cells, are associated with the most aggressive and recurring cancers. The finding suggests that testing for ferroportin levels in women with breast cancer may one day help doctors to more accurately predict whether their patients' cancer will return. It may also help some women with high levels of the protein to avoid invasive or toxic treatments such as chemotherapy.

The study, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), of the National Institutes of Health (NIH), appears today in the online version of the journal Science Translational Medicine.

"Ferroportin expression may help predict whether women who have had breast cancer will relapse or not," said Frank M. Torti, M.D., M.P.H., director of the Comprehensive Cancer Center at WFUBMC, senior author on the paper and co-lead investigator for the study. The findings also suggest that levels of ferroportin may eventually help guide therapy for breast cancer patients.

"There is a group of high-risk women with breast cancer who have high ferroportin levels and do quite well," Torti said. "We may eventually be able to adjust our treatments so that these patients can avoid chemotherapy and all the side effects that go along with it. The ability to predict which women will be okay without such intense treatment would be a tremendous help."

The findings are the result of a series of experiments by Torti and colleagues at WFUBMC.

Drawing on the hypothesis that iron may be altered in breast cancer and that the alteration might be important in the behavior of the cancer, the researchers first looked at isolated human breast cancer cells and found that there was a significant reduction of ferroportin in the cancerous cells compared to that of normal breast cells.

There are changes in many of the genes and proteins in cancer cells, Torti explained, so the researchers next explored whether the reduction in ferroportin in cancer cells directly contributed to the growth of the cancer or whether it was simply a consequence of the disease. To do this, the researchers artificially increased ferroportin to near normal levels in an aggressive breast cancer cell line in which ferroportin levels were initially very low. Using a mouse model, the researchers watched the growth of tumors formed by these cells, and found that the ones in which the levels of ferroportin had been restored to normal grew more slowly than the tumors formed by cells with depleted levels of the protein.

"The reason for that is simple," explained Suzy V. Torti, Ph.D., an associate professor of biochemistry at Wake Forest Baptist and co-lead investigator on the paper. "In the case of cancer, the ability to remove iron from cells is reduced by the depleted ferroportin levels, and as a result, iron accumulates in cancer cells. Cancer cells require iron, which allows the tumor to grow faster and perhaps become more aggressive. Because ferroportin can remove iron from the cell, when we put the protein back into the cell, the ferroportin removed the cancer's growth stimulus. Our findings suggest that ferroportin is a substantial influence on the behavior of the cancer."

She noted that though the iron at issue acts as a growth stimulus for cancer, the study focused on cellular and not dietary iron or iron supplements. When regulated appropriately, iron is vital to all cell development including that of healthy cells and patients should not change the amount of iron in their diets.

Next, the researchers looked at ferroportin levels in human breast cancer tissue. As predicted, they found that ferroportin levels were lowest in the most aggressive areas of cancer, confirming that the relationship does not only occur in cell culture and isolated breast cancer cells, but also in the actual tissue of women with cancer.

So, the Tortis and their team, including Lance D. Miller, Ph.D., a bioinformatics expert, proceeded to explore four large study databases of breast cancer patients to see if ferroportin levels in human breast cancer were associated with long-term outcomes. The data included gene expression information at the time of diagnosis and multi-year clinical follow-up for more than 800 breast cancer patients from around the world.

"Uniformly, we found that ferroportin levels were a strong predictor of the propensity for a woman's breast cancer to recur," Frank Torti said. "It's a striking prediction. This marker separates women into good and poor prognostic groups independently from any other factors such as tumor size, grade, lymph node status, or other conditions."

The researchers' next step, he added, will be to extend their results to larger populations that include women of various ethnicities and demographics.

"We are excited that we, and our Cancer Center, have made a discovery that not only increases our understanding of the basic biology of breast cancer, but may eventually be directly useful in treating patients," Frank Torti said.


Contact: Jessica Guenzel
Wake Forest University Baptist Medical Center

Related medicine news :

1. New and Delicious, Almond Butter Filled, Cookie Bites With 35.7% Protein to Help Manage Weight and Build Muscle
2. Research highlights role of protein pair in obesity regulation
3. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
4. Smithfield, United Food and Commercial Workers Union, and Food Networks Paula Deen to Deliver 150,000 Servings of Protein to San Francisco Food Bank
5. Protein Sciences Corporation Announces Profitable and Cash Flow Positive Results for 2009 and Management Realignment
6. Protein Appears Key to Intestinal Balance
7. SIBLING proteins may predict oral cancer
8. Damaged protein identified as early diagnostic biomarker for Alzheimers disease in healthy adults
9. Cells of aggressive leukemia hijack normal protein to grow
10. Omega Protein Comments on California Lawsuit Alleging Fish Oil Contaminants
11. Proteins May Predict Spread of Colon Cancer
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Speech ... who believe that with innovative technologies and under the right circumstances, these practices ... the benefit of a dual-approach to his or her therapeutic sessions, as well ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... the 1980s we have seen vast improvements in scientific research and discoveries, leading ... strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform ...
(Date:12/1/2015)... ... December 01, 2015 , ... The ... been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s first portable ... Meeting from November 29 to December 4, 2015. , MED-TAB is expected ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken at ... accurate interpretation by the radiologist. The marking utensils are so small, however, they ... found a way to alleviate this problem. , He developed the patent-pending MARK ...
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. ... that the organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior ... award celebrates exceptional special needs providers that excel in synthesizing the areas of ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 Breg, ... and services, announced today that it has been awarded ... organization. Members served by Novation will have access to ... sports bracing products and soft goods dedicated to advancing ... --> The aging U.S. population, rising prevalence of ...
(Date:12/1/2015)... , Dec. 1, 2015 Building on ... Johnson & Johnson (NYSE: JNJ ) today ... Pharmaceutical Companies to significantly reduce the burden of ... up 74 percent of new HIV infections among ... World AIDS Day, these new initiatives include collaborations ...
(Date:12/1/2015)... YORK , Dec. 1, 2015 Relmada Therapeutics, ... the treatment of chronic pain, announced today that the company ... will be held December 1-3 at the Luxe Sunset Boulevard ... Sergio Traversa , CEO of Relmada Therapeutics, will present on ... Eastern Time). . Please register at least ...
Breaking Medicine Technology: